A Bayesian Phase I/II Trial Design for Immunotherapy

DOI10.1080/01621459.2017.1383260zbMath1402.62278OpenAlexW2758838926WikidataQ91332747 ScholiaQ91332747MaRDI QIDQ4559685

Ying Yuan, Beibei Guo, Suyu Liu

Publication date: 4 December 2018

Published in: Journal of the American Statistical Association (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc6860919

zbMATH Keywords

immune responseimmunotherapydose findingphase I/II trialBayesian adaptive designrisk-benefit tradeoff

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10)

Cites Work

• Unnamed Item
• Unnamed Item
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials

This page was built for publication: A Bayesian Phase I/II Trial Design for Immunotherapy